Special Issue “State-of-the-Art Cancer Immunotherapies—2nd Edition”
International Journal of Molecular Sciences · 23.04.2026 · 27 (9) · 3740
DOI: 10.3390/ijms27093740 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.04.2026. Verfasst von Hisashi Nagase und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Parasitology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer immunotherapy harnesses the immune system to combat tumor cells [...]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Parasitology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
- Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, CCII Bristol Myers Squibb Building, Yoshida-Konoe-cho, Sakyo-k…
- Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.
ORCID-Profile: Takayuki Yoshimoto
Zitieren
APA
Nagase, H., Kato, T., & Yoshimoto, T. (2026). Special Issue “State-of-the-Art Cancer Immunotherapies—2nd Edition”. International Journal of Molecular Sciences, 27(9), 3740. https://doi.org/10.3390/ijms27093740
Vancouver
Nagase H, Kato T, Yoshimoto T. Special Issue “State-of-the-Art Cancer Immunotherapies—2nd Edition”. International Journal of Molecular Sciences. 2026;27(9):3740. doi:10.3390/ijms27093740
BibTeX
@article{Nagase2026,
author = {Nagase, Hisashi and Kato, Takuma and Yoshimoto, Takayuki},
title = {Special Issue “State-of-the-Art Cancer Immunotherapies—2nd Edition”},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {9},
pages = {3740},
doi = {10.3390/ijms27093740}
}
EUVIMED